Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biotherapy for lymphoma.

P McLaughlin1

  • 1Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 68, Houston, TX 77030, USA. pmclaugh@notes.mdacc.tmc.edu

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2022
Same author

How does a lifetime of painful experiences influence sensations and beliefs about pain in adults with severe haemophilia? A qualitative study.

Disability and rehabilitation·2021
Same author

The experiences and beliefs of people with severe haemophilia and healthcare professionals on pain management, and their views of using exercise as an aspect of intervention: a qualitative study.

Disability and rehabilitation·2021
Same author

Retrospective study of first episode psychosis in the Dublin Southwest Mental Health Service: demographics, clinical profile and service evaluation of treatment.

Irish journal of psychological medicine·2019
Same author

Recommendations on multidisciplinary management of elective surgery in people with haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Rituximab, an anti-CD20 antibody, is a key treatment for B-cell cancers. New research explores novel antibody therapies, cytokines, and immune system modulation for improved cancer treatment strategies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Unconjugated anti-CD20 monoclonal antibody, rituximab, is established for B-cell malignancies.
  • Emerging therapies include novel antibody formats, cytokines, and immune-based strategies.

Purpose of the Study:

  • To review current and emerging biotherapy approaches for B-cell malignancies.
  • To highlight advancements in monoclonal antibodies, cytokines, and immune modulation.

Main Methods:

  • Review of current literature on monoclonal antibodies (e.g., rituximab, CAMPATH-1H, anti-CD22).
  • Exploration of cytokine therapies (e.g., interferon-alpha, interleukin-2, interleukin-12).
  • Discussion of radioimmunotherapy, T-cell response exploitation, vaccine strategies, and dendritic cell roles.

Related Experiment Videos

Main Results:

  • Rituximab is a cornerstone therapy with evolving applications in dosing and combinations.
  • Other unconjugated antibodies and radioimmunotherapy represent rapidly developing fields.
  • Cytokines and immune-based strategies, including T-cell responses and dendritic cells, show significant therapeutic potential.

Conclusions:

  • Biotherapy offers a diverse and expanding range of treatment options for B-cell malignancies.
  • Future directions focus on harnessing the immune system through novel antibodies, cytokines, and cellular therapies.
  • Integrated immunotherapeutic approaches hold promise for improved patient outcomes.